for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Scpharmaceuticals Inc

SCPH.OQ

Latest Trade

5.40USD

Change

-0.21(-3.74%)

Volume

10,904

Today's Range

5.40

 - 

5.76

52 Week Range

2.46

 - 

7.65

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Scpharmaceuticals Qtrly Loss Per Share $0.31

Nov 12 (Reuters) - scPharmaceuticals Inc <SCPH.O>::SCPHARMACEUTICALS INC. REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.SCPHARMACEUTICALS INC - EXPECTS YEAR END 2019 CASH AND CASH EQUIVALENTS AND INVESTMENT SECURITIES TO BE APPROXIMATELY $65-$70 MILLION.SCPHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.31.SCPHARMACEUTICALS INC - ENDED Q3 WITH $83.7 MILLION IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH.

Scpharmaceuticals Provides Furoscix Update And Announces Completion Of $20 Mln Term Loan Agreement

Sept 18 (Reuters) - scPharmaceuticals Inc <SCPH.O>::SCPHARMACEUTICALS INC. PROVIDES FUROSCIX® UPDATE AND ANNOUNCES COMPLETION OF $20.0 MILLION TERM LOAN AGREEMENT.SCPHARMACEUTICALS INC - CONTINUED PROGRESS ON FUROSCIX; CONFIRMING PLANNED RESUBMISSION OF FUROSCIX NDA WITH FDA BY MID-YEAR 2020.SCPHARMACEUTICALS INC - COMPLETED $20.0 MILLION TERM LOAN WITH SOLAR CAPITAL LTD. AND SILICON VALLEY BANK.SCPHARMACEUTICALS INC - PROCEEDS FROM LOAN WILL BE USED TO PAY OFF EXISTING $10.0 MILLION TERM LOAN ALONG WITH RELATED FEES AND EXPENSES.SCPHARMACEUTICALS INC - RESTATED AND AMENDED AGREEMENT EXTENDS TERM OF CREDIT FACILITY UNTIL SEPTEMBER 17, 2023.SCPHARMACEUTICALS - REITERATING PRIOR GUIDANCE AND REMAINS CONFIDENT CO WILL RESUBMIT FUROSCIX NDA WITH U.S. FDA BY MID-YEAR 2020.

scPharmaceuticals Inc. Reports Q2 Loss Per Share $0.53

Aug 7 (Reuters) - scPharmaceuticals Inc <SCPH.O>::SCPHARMACEUTICALS INC. REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.SCPHARMACEUTICALS INC - EXPECTS YEAR END 2019 CASH AND CASH EQUIVALENTS AND INVESTMENT SECURITIES TO BE APPROXIMATELY $55-$58 MILLION..SCPHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.53.

scpharmaceuticals Inc. Provides Regulatory Update On FUROSCIX

July 16 (Reuters) - scPharmaceuticals Inc <SCPH.O>::SCPHARMACEUTICALS INC. PROVIDES REGULATORY UPDATE ON FUROSCIX®.SCPHARMACEUTICALS INC - CO ACCELERATES TIMELINE AND NOW EXPECTS RESUBMISSION OF FUROSCIX NDA WITH FDA BY MID-YEAR 2020.SCPHARMACEUTICALS INC - FDA CONFIRMED THAT RESUBMISSION WOULD BE UNDER CURRENT NDA.

scPharmaceuticals Inc Reports Quarterly Loss Per Share Of $0.47

May 8 (Reuters) - scPharmaceuticals Inc <SCPH.O>::SCPHARMACEUTICALS INC. REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.SCPHARMACEUTICALS INC QUARTERLY LOSS PER SHARE $0.47.

Scpharmaceuticals Inc Quarterly Loss Per Share $0.27

scPharmaceuticals Inc <SCPH.O>::SCPHARMACEUTICALS INC. REPORTS FOURTH QUARTER AND YEAR ENDED 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.SCPHARMACEUTICALS INC QUARTERLY LOSS PER SHARE $0.27.SCPHARMACEUTICALS INC - RESUBMISSION OF FURSOCIX WITH U.S. FOOD AND DRUG ADMINISTRATION (FDA) BY YEAR-END 2020.

Scpharmaceuticals Inc - Co entered into a development agreement with West Pharmaceutical Services Inc - SEC Filing

Jan 29 (Reuters) - scPharmaceuticals Inc <SCPH.O>::SCPHARMACEUTICALS INC - ON JANUARY 28, 2019, CO ENTERED INTO A DEVELOPMENT AGREEMENT WITH WEST PHARMACEUTICAL SERVICES, INC - SEC FILING.SCPHARMACEUTICALS INC - UNDER TERMS OF DEVELOPMENT AGREEMENT, CO PAID TO WEST A ONE-TIME UPFRONT PAYMENT OF ABOUT $1.7 MILLION UPON SIGNING OF AGREEMENT.SCPHARMACEUTICALS INC - CO ISSUED TO SENSILE MEDICAL AG NOTICE OF TERMINATION FOR BUSINESS REASONS UNDER LICENSE AGREEMENT, DATED AS OF JUNE 29, 2015.SCPHARMACEUTICALS INC - TERMINATION OF LICENSE AGREEMENT WITH SENSILE MEDICAL AG WILL BECOME EFFECTIVE AS OF MARCH 30, 2019.SCPHARMACEUTICALS INC - CO AND TROY IGNELZI, CO'S CFO AGREED TO END IGNELZI'S EMPLOYMENT WITH CO AND ITS SUBSIDIARIES EFFECTIVE FEB 28, 2019.SCPHARMACEUTICALS INC - BOARD APPOINTED RACHAEL NOKES TO SUCCEED IGNELZI AS CO'S PRINCIPAL ACCOUNTING OFFICER.SCPHARMACEUTICALS INC - BOARD APPOINTED JOHN TUCKER TO SUCCEED IGNELZI AS CO'S PRINCIPAL FINANCIAL OFFICER.

scPharmaceuticals Files For $100 Mln Mixed Shelf Offering

Jan 3 (Reuters) - scPharmaceuticals Inc <SCPH.O>::SCPHARMACEUTICALS INC FILES FOR $100 MILLION MIXED SHELF OFFERING - SEC FILING.

scPharmaceuticals Reports Q3 Loss Per Share $0.31

Nov 13 (Reuters) - scPharmaceuticals Inc <SCPH.O>::SCPHARMACEUTICALS INC. REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.QTRLY LOSS PER SHARE $0.31 .RESUBMISSION OF FURSOCIX WITH U.S. FDA BY YEAR-END 2019.EXPECTS YEAR END 2018 CASH AND CASH EQUIVALENTS AND INVESTMENT SECURITIES TO BE ABOUT $82 - $87 MILLION.FORECASTS 2019 EXPENDITURES OF $8 - $10 MILLION PER QUARTER.Q3 EARNINGS PER SHARE VIEW $-0.53 -- THOMSON REUTERS I/B/E/S.

Scpharmaceuticals Provides Regulatory Update On Furoscix

Oct 18 (Reuters) - scPharmaceuticals Inc <SCPH.O>::SCPHARMACEUTICALS INC. PROVIDES REGULATORY UPDATE ON FUROSCIX®.SCPHARMACEUTICALS INC - TYPE A POST-ACTION MEETING MINUTES RECEIVED.SCPHARMACEUTICALS - FDA ASKED CO TO CONDUCT ADDITIONAL HUMAN FACTORS STUDIES, DOSE DELIVERY VALIDATION STUDY WITH RECENTLY MODIFIED FUROSCIX INFUSOR.SCPHARMACEUTICALS INC - INTENDS TO SUBMIT REQUESTS FOR TYPE C MEETINGS WITH FDA TO DETERMINE STUDY PROTOCOLS.SCPHARMACEUTICALS INC - FDA HAS NOT REQUESTED ANY ADDITIONAL CLINICAL TRIALS.SCPHARMACEUTICALS INC - FDA CONFIRMED APPROPRIATE POPULATIONS FOR FUROSCIX.SCPHARMACEUTICALS INC - "REMAIN IN A STRONG FINANCIAL POSITION WITH EXPECTED YEAR-END CASH OF $80-85 MILLION".SCPHARMACEUTICALS-FDA SAYS LABEL SHOULD SAY FUROSCIX INFUSOR NOT TO BE SUBSTITUTED FOR IV DIURETICS IN PATIENTS NEEDING HOSPITALIZATION/RECENTLY DISCHARGED.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up